By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biotech startup KellBenx announced on Monday a licensing agreement with Cedars-Sinai Medical Center in Los Angeles for three interleukin biomarkers for the development of a blood-based test to predict premature births.

According to the KellBenx, the agreement is the first step to the possible development of a minimally invasive test that can predict preterm delivery early in pregnancy or even before a woman becomes pregnant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.